Efti in Combination with Pembrolizumab Achieves Excellent Initial Overall Survival Benefit in 1L NSCLC
“Efti’s clinical results achieved to date in combination with pembrolizumab are increasingly robust and continue to justify the attention given to this novel IO-IO combination through invitations to make oral presentations at two prestigious conferences, ASCO and SITC, last year. We now are showing excellent initial overall survival, which is the gold standard benchmark within oncology, across the entire intent-to-treat population of 1st line NSCLC patients in our Phase II trial. For non-small cell lung cancer patients with >1% PD-L1 expression, a key focus for future development and for which efti in combination with pembrolizumab has Fast Track status, the survival benefit is impressive. We look forward to presenting more mature data at a major medical conference later this year,” said Marc Voigt, Immutep’s CEO.
Share:
More News
“KEYTRUDA has helped transform the treatment of certain cancers, and we continue to pursue innovations that build on this breakthrough medicine to give patients and those who treat them better experiences,” said Dr. Marjorie Green, senior vice president and head of oncology, global clinical development, Merck Research Laboratories. “If approved,
“We are disappointed for ovarian cancer patients desperately lacking new treatment options. There has been a great deal of work across the industry in this immunologically cold tumor, yet there are still few treatment options that improve survival in this very difficult-to-treat tumor type. We are still on track to
“The improvement in survival seen in ROSELLA, without an increased safety burden, brings us closer to delivering a new standard-of-care treatment for patients with platinum-resistant ovarian cancer,” said Bill Guyer, PharmD, Corcept’s Chief Development Officer. “We deeply appreciate the patients and investigators who participated in the trial, and we look
“We are grateful for the ongoing guidance and support from the FDA and are very pleased that the agency is fully aligned on our plans related to the Phase 3 trial,” said Stacy Lindborg, Ph.D., president and chief executive officer of IMUNON. “The Phase 2 OVATION 2 study data are
